期刊文献+

氨氯地平对比索洛尔在大鼠体内药动学的影响 被引量:1

Effect of amlodipine on the pharmacokinetics of bisoprolol in rats
暂未订购
导出
摘要 目的探讨氨氯地平对比索洛尔在大鼠体内药动学的影响。方法 12只大鼠随机分为两组,一组给予比索洛尔灌胃,另一组给予比索洛尔与氨氯地平灌胃,分别采用液相色谱-串联质谱法测定两组大鼠血浆中比索洛尔的血药浓度。用DAS2.0程序软件拟合药动学参数,比较两者的药动学参数。结果单独给药组和联合给药组的主要药动学参数:Cmax分别为(513.36±56.02)和(585.21±77.52)ng/ml,t1/2:(1.30±0.51)和(1.51±0.65)h,AUC0-t:(433.70±50.98)和(721.16±218.09)ng/(h.ml),CL/F:(38.02±5.63)和(25.9±5.18)L/(h.kg),两组间AUC0-t和CL/F的差异具有统计学意义(P<0.05)。结论建立的液相色谱-串联质谱法专属性、准确性、灵敏度适宜。氨氯地平可延长比索洛尔在大鼠体内的吸收和排泄,对比索洛尔的药代动力学有显著影响。 Objective To study the effect of amlodipine on the pharmacokinetics of bisoprolol in rats. Methods Twelve rats were randomly divided into two equal groups : A and B. Rats of group A were given bisoprolol. Rats of group B were given bisoprolol and amlodipine. Blood samples were taken from the animals for the determination of the plasma concentration of amlodipine by liquid chro- matography - mass spectrometry/mass spectrometry ( LC - MS/MS). The pharmacokinetics parameters together were calculated using DAS program to evaluate each of the two preparations and the pharrnacokinetic parameters were statistically compared. Results The main pharmaeokinetic parameters of the two groups were as follows: Cmax: (513. 36±56. 02) and (585.21±77.52) ng/ml, tl/2 : (1.30±0.51) and (1.51±0.65) h, AUC0-1 (433.70±50.98) and (721.16±218.09) ng/(h·ml), CL/F: (38.02±5.63) and (25.9±5.18 ) L/( h·kg). The pharmacokinetics parameters of AUC0 -1 and CL/F showed significant difference between the two groups(P 〈 0.05 ). Conclusions The LC -MS/MS method is specific and sensitive. The amlodipine has significant effect on the pharmacokineties of bisoprolol with extending of absorption and excretion in rats.
出处 《武警医学》 CAS 2013年第4期319-322,共4页 Medical Journal of the Chinese People's Armed Police Force
关键词 氨氯地平 比索洛尔 药动学 液相色谱-串联质谱 amlodipine bisoprolol pharmacokineties LC - MS/MS
  • 相关文献

参考文献6

二级参考文献16

  • 1孙宁玲.β受体阻滞剂,还是高血压的一线用药吗?[J].中国处方药,2006,5(1):4-7. 被引量:1
  • 2龚培力.抗高血压药物的评价与研究进展[J].医药导报,2007,26(4):334-339. 被引量:62
  • 3Topol EJ. Hypertensive hypertrophic card iomyopathy of the elderly[J]. NE ngl JMed, 1985,312:277 - 283.
  • 4Zieman SJ, Fortuin NJ. Hypertrophic and restrictive cardiomyopathies in the elderly [ J ]. Cardiol Clinics, 1999,17 : 159 - 172.
  • 5Karam R, Lever HM. Hypertensive hypertrophic cardiomyopathy or hy- pertrophic cardiomyopathy with hypertens on? A study of 78 patients [ J ]. J Am Coil Cardiol, 1989,13:580 - 584.
  • 6Tskeda A, Takeda N. Different pathophysiology of cardiac hypertrophy in hypertension and hypertrophic cardiornyopathy [ J 1-J Mol Cell Cardiol, 1997,29:2961 - 2965.
  • 7Shapiro LM. Hypertrophic cardiomyopathy in the elderly [ J ]. Br Heart J, 1990,63:265 - 266.
  • 8Siu CW, Lau CP,Tse HF. Prevention of atrial fibrillation recur-rence by statin therapy in patients with lone at rial fibrillation af tersuceessful car- dioversion [ J ] . Am J Cardiol,2003,92 ( 11 ) : 1343 - 1345.
  • 9Pepine C J,Handberg EM,Cooper-DeHoff RM,et al.A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease.The International Verapamil-Trandolapril Study (INVEST):a randomized controlled trial.JAMA,2003,290:2805-2816.
  • 10Weber MA,Julius S,Kjeldsen SE,et al.Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.Lancet,2004,363:2049-2051.

共引文献763

同被引文献17

  • 1Chobanian A V,Bakris G L,Black H R,et al.Seventh report of the Joint National Committee on prevention,detection,evaluation,and treatment of high blood pressure[J].Hypertens,2003,42:1206-1252.
  • 2Mancia G,De Backer G,Dominiczak A,et al.2007 guide-lines for the management of arterial hypertension.The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Hypertension,2007,25:1105-1187.
  • 3Allemann Y,Fraile B,Lambert M,et al.Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy:the Exforge in Failure after Single Therapy (EX-FAST) study[J].Clin Hypertens,2008,10:185-194.
  • 4Brachmann J,Ansari A,Mahla G,et al.Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy[J].Adv Ther,2008,25:399-411.
  • 5Liebson P R.Calcium channel blockers in the spectrum of antihypertensive agents[J].Expert Opin Pharmacother,2003,7:2385-2401.
  • 6Miura S,Saku K.Efficacy and safety of angiotensin Ⅱ type 1 receptor blocker/calcium channel blocker combination therapy for hypertension:focus on a single-pill fixed-dose combination of valsartan and amlodipine[J].J Int Med Res,2012,40(1):1-9.
  • 7Flack J M,Calhoun D A,Satlin L,et al.Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension:the EX-STAND study[J].Hum Hypertens,2009,23:479-489.
  • 8Philipp T,Smith T R,Glazer R,et al.Two multicenter,8-week,randomized,double-blind,placebo-controlled,parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension[J].Clin Ther,2007,29:563-580.
  • 9Schunkert H,Glazer R D,Wernsing M,et al.Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy[J].Curr Med Res Opin,2009,25:2655-2662.
  • 10Sinkiewicz W,Glazer R D,Kavoliuniene A,et al.Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy[J].Curr Med Res Opin,2009,25:315-324.

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部